Sigyn Therapeutics (SIGY) 10-K2022 FY Annual report

Filed: 31 Mar 23, 6:14am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adulteration, agency, Ajay, Alexander, anticoagulant, Ari, attorney, back, Baxter, BCT, bifurcated, Bio, biomedical, biopharmaceutical, biotechnology, bioterror, Boston, cell, Charlene, ChemoPrep, ChemoPrepTM, ChemoPure, ChemoPureTM, chemotherapeutic, chemotherapy, clarification, clinician, clock, clot, clotting, compromised, concentrated, constituted, convened, Cosmetic, Counsel, Cytori, decoy, deny, developmental, deviation, diminish, diminishing, disapprove, Doctor, Donald, Dorst, emit, endeavor, endotoxemia, enrolled, Eric, ESRD, export, FASN, fifteen, fuelled, fuelling, goal, greatest, gut, halted, Hamilton, Hemolife, heparin, Hepatology, Hillebrand, implantable, insight, intestinal, IP, IRB, Jefferson, Jersey, Johnson, joining, Kluger, laboratory, Lane, leader, longer, Lybrand, Lynam, machine, mandate, MBA, MD, median, Microbiology, misbranding, Nad, Nand, notification, Nursing, Oregon, outweigh, Owen, panel, permeability, Persistent, PhD, PHEMCE, Philadelphia, polycarbonate, polyethersulphone, pore, portable, post, preapproval, predicate, premarket, prescribing, QSR, quantified, quantify, quantity, radiation, rateably, reconvened, reengineering, refund, repair, reset, restructure, Richa, rigorously, Rock, sacrificing, saturation, Savoir, secondary, SeeCommerce, shear, Sinai, sit, site, sound, SpectraScience, Spring, substantive, Surgery, Tammy, Terumo, TherapyTM, thought, threat, trial, tumour, uplist, Valley, Verdisoft, Verma, veteran, Vice, withdraw, Yevzlin

Removed: Assignment, assumption, attract, Australian, began, Bill, borrowed, bylaw, capitalizing, Chaya, choose, claim, clause, Cloud, Collateral, computing, Confidentiality, developed, dispute, element, elimination, Extensible, formatted, gain, guarantor, guaranty, hearing, hosting, identification, inaction, incentive, indemnified, indexed, inherently, initiate, inquiry, intrinsic, investigation, Joseph, language, larger, license, notional, offsetting, participate, portrayal, proprietary, prospectively, repricing, resolution, retrospectively, revalued, secured, security, Segelman, separated, software, suit, updated, utilized

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SIGY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Sigyn Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Joyce, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

This certificate is being made for the exclusive purpose of compliance by the Chief Executive Officer of the Company with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be disclosed, distributed or used by any person or for any reason other than as specifically required by law.

/s/ James Joyce
James Joyce
Chief Executive Officer (Principal Executive Officer)

March 31, 2023